Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 27, 2025
Product Development
Crispr Therapeutics: Controlled risk for accelerated development
An ex vivo gene knockout approach helped the company become first to market with a gene editing therapy
BioCentury | Feb 25, 2025
Product Development
Indication selection: Lessons learned from the CRISPR-Cas9 story
Founding CEOs of gene editing companies discuss their pipeline strategies and lessons learned
BioCentury | Dec 10, 2024
Product Development
Gene and base editors deliver on fetal hemoglobin expression: ASH24
Editas, Beam report updates on sickle cell genetic therapies at this year’s ASH meeting
BioCentury | Nov 20, 2024
Discovery & Translation
Science Spotlight: A new obesity target may avoid nausea, muscle loss
BioCentury’s roundup of translational innovation: Embark/Novo discover new obesity target, Canbridge delivers large DMD gene, and more
BioCentury | Nov 5, 2024
Product Development
Arcus data the latest twist in the TIGIT story
BioCentury’s Clinical Report also analyzes the impact of a patient death in Beam’s trial, plus data from Cogent, Disc, Essa and Novo
BioCentury | Oct 28, 2024
Product Development
In vivo editing data advances lift hopes for better access
Editas and Tessera report preclinical data for in vivo stem cell editors; Interius doses first patient with an in vivo CAR T
BioCentury | Oct 11, 2024
Product Development
Discovery through perturbation: taking causality into your own hands
A company’s experimental setup and scale shape the type of AI it uses and questions it can ask
BioCentury | Sep 26, 2024
Product Development
Sickle cell mechanisms that could fill the hole left by Pfizer’s Oxbryta withdrawal
Following the market withdrawal of Pfizer’s Oxbryta, demand rises for sickle cell therapies with global potential
BioCentury | Sep 18, 2024
Product Development
Data from Merck, Daiichi could support first approval for HER3 ADC
In BioCentury’s latest clinical report, Merck-Daiichi product scores on PFS after setback at FDA, plus updates from Ascendis, Boehringer, Atea and more
BioCentury | May 24, 2024
Product Development
J&J data at ASCO probe new target space, toxicity limits for actinium
The radiotherapy is one of multiple modalities J&J is testing against KLK2, which could enable tumor-specific targeting across prostate cancer stages
Items per page:
1 - 10 of 1638